Pre-Pandemic Timeline
2016 – 2018
Chronological order of significant global, Australian and SA data points leading up to the COVID-19 Pandemic.
Navigate the timeline pages:
1800s | 1900-1945 | 1946-1979 | 1980-1999 | 2000-2015 | You Are Here | 2019 | 2020 | 2021 | 2022 | 2023
Best viewed on a large screen
Data points are continuously being added so please come back again soon
The UN 17 Sustainable Development Goals (SDGs) begin
US Military-Industrial-Academic technology bio-partnership framework is set
On January 11, 2016 it was announced that “the U.S. Army Contracting Command, Picatinny Arsenal, New Jersey, on behalf of the Joint Project Manager for Medical Countermeasure Systems (JPM-MCS) through the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), announced its intent to enter into a Section 815 Other Transaction (OT) Agreement with the National Chemical and Biological Defense Consortium (NCBDC) for a period of twenty (20) years. ” [1]
NCBDC “encompasses the expertise, knowledge, technologies, and innovation to meet the program objectives and goals of the coordinated research and development program designed to support the Department of Defense’s medical, pharmaceutical, and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.” It includes pharma industry, academic institutions, and not-for-profit partners, “forad vanced development efforts to support the Department of Defense’s (DoD) medical, pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel”. [1, 4]
The NCBDC is an open consortium with a low barrier for membership. Any interested company, academic institution, or contractor can become a member and join the consortium to widen knowledge and technical expertise to continue to advance in technologies and meet Government needs.
- On April 8, 2016, the OTA was finalized and the Government executed OTA W15QKN-16-9-1 to conduct collaborative, prototype research projects with NCBDC members with a cumulative value up to $10B over the next 20 years – called Requests for Prototype Proposals (RPPs)
- The NCBDC changed its name to Medical CBRN Defense Consortium (MCDC). It is for the “distinct purpose of collaborating to provide quick and efficient delivery of (chemical, biological, radiological or nuclear) CBRN defense medical capabilities for the Joint Force under the DoD Chemical and Biological Defense Program (CBDP)” The first RPP solicitation was released on June 22, 2016
- In June 2017 MCDC attended the BIO industries’ (a lobby group) BIO conference, and in 2018 [5]
On July 21, 2020 following a RPP, the MCDC awarded a contract to Pfizer-BioNTech to accelerate their COVID-19 vaccine. [2, 3]
UN hold first ID2020 summit
On May 20, 2016 the United Nations held the first ID2020 summit in New York, which is now held annually. The United Nations recognizes “identity as a fundamental human right“, and ID2020 is a strategic, global initiative launched in response to Sustainable Development Goal 16.9., with the aim “by 2030, provide legal identity to all, including birth registration” [1]
“Together we will foster a global conversation and build a working coalition to identify and build the enabling conditions for the creation of a legal digital identity for all individuals at risk“. The UN claims that one fifth of the worlds population is without a recognised legal ID which makes them “invisible to society and vulnerable to trafficking, prostitution, and child abuse.”
Then the ID2020 Alliance launched in 2017 as a global public-private partnership setting the future course of digital identity (ID), ensuring that digital identity is responsibly implemented and widely accessible, as they state no government, company or agency can solve this challenge alone. Its partners include Microsoft, the Rockefeller Foundation, Accenture, GAVI (a core partner of the WHO), UNICEF, the Bill & Melinda Gates Foundation and the World Bank. [2, 3]
WHO R&D Blueprint for action to prevent epidemics
Spurred by the West Africa Ebola epidemic, and “at the request of its 194 Member States”, in May 2015, “the World Health Organization (WHO) convened a broad coalition of experts to develop an R&D Blueprint for Action to Prevent Epidemics”. A year later, at the May 24, 2016 World Health Assembly (WHA), Members States welcomed the development of the R&D Blueprint” or Health Emergencies Program.
All because infectious disease outbreaks are “inevitable” due to more “frequent travel, globalized trade and greater interconnectedness between countries.” [2]
The R&D Blueprint is a global strategy and preparedness plan that allows the rapid activation of research and development activities during epidemics. Its aim is to fast-track the availability of effective tests, vaccines and medicines that can be used to save lives and avert large scale crises.
The R&D Blueprint uses a list of identified priority diseases and an unknown “Disease X”. For each disease an R&D roadmap is created, followed by target product profiles. This is then used to guide the response to outbreaks in both urgent action and in developing ways to improve the global response for future epidemics.
On December 10, 2015 the WHO released its first (of what will be an annual) “list of top emerging diseases likely to cause major epidemics”. “This priority list forms the backbone of the new WHO Blueprint for R&D”. “The group of experts who developed the list represented a range of disciplines, including virology, microbiology, immunology, public health, clinical medicine, mathematical and computational modelling, product development, and respiratory and severe emerging infections. The conclusions of the experts were reviewed by the Blueprint’s independent Scientific Advisory Group.”
Interestingly “other diseases were designated as ‘serious’, requiring action by WHO to promote R&D; as soon as possible” included “thrombocytopaenia syndrome” – a adverse event seen from 2021 following COVID-19 vaccination! [1]
G20 Declaration on 8 July 2017:
“We support the WHO´s central coordinating role, especially for capacity building and response to health emergencies…Furthermore, we see a need to foster R&D preparedness through globally coordinated models as guided by the WHO R&D Blueprint, such as the Coalition for Epidemic Preparedness Innovations (CEPI).” [3]
COVID-19 roadmap was prepared following February 11, 2020 meetings – ARCHIVE
UN Global Health Crisis Task Force is established
Global Health Crises Task Force was established by the UN Secretary-General to support and monitor global response to health crises. The Task Force was represented by UN, WHO, World Bank Group and infectious disease experts such as Dr Anthony Fauci
Russiagate begins: Creating the fake Steel Dossier to “Get Trump”
[Hindsight revealed by May 2023 Durham report] During a meeting in London on July 5, 2016 FBI “Handling Agent-I” [pg 87] received the first “Report” from ex-MI6 agent Christopher Steele, who alleged presidential candidate Donald Trump was colluding with Russia to win the 2016 election.
That agent said “his initial reaction to Steele’s allegations of Trump-Russia collusion was one of “disbelief” and that Steele was “politically motivated” but he passed the allegations up the FBI chain anyway. He appeared to be aware that Clinton’s campaign was connected to Steele’s work, including the notation “HC” in his notes. [1]
This would begin what is known as the Steel Dossier, now discredited and known to be funded by Hillary Clinton’s campaign. The FBI used this information to open up an investigation into her opposition candidate, and fuelled the chain of events that led to spying on Trump’s campaign – referred to colloquially as Russiagate.
The ongoing, now known to be baseless investigation, undercut Trump’s entire time as President, robbing the American people of the true pursuit of the “rule of law” and truth.
UN Global Compact on Migration begins
On September 19, 2016 at a United Nation intergovernmental conference in New York on Refugees and Migration, following July 2016 discussions and on the back the 2015 signing of Agenda 2020, the UN adopted a global compact for safe, orderly and regular migration. Noting that “Forced displacement and irregular migration in large movements… often present complex challenges.”
The drivers of migration are said to include “adverse effects of climate change, natural disasters and human made crises… poverty eradication, conflict prevention and resolution.” In adopting the 2030 Agenda for Sustainable Development the UN recognized a “positive contribution made by migrants” to their agenda.
The UN documentation on migration dates back to 2013 and 2015, following 2016 stand they revisited their policy position in 2017, 2018 and in 2022.
“In 2018, Member States agreed to review the progress made at the local, national, regional and global levels in implementing the Global Compact for Safe, Orderly and Regular Migration (GCM) in the framework of the United Nations through a State-led approach and with the participation of all relevant stakeholders”
Fast forward to 2022 through this agreement with the Biden administration and the UN the “Global Compact for Migration” creates the infrastructure to facilitate massive free, organised illegal entry into the United States for un-vetted immigrants to invade the United States, including CCP agents and known terrorists. [1, 2, 3, ]
Many countries, including Australia, have been experiencing massive unprecedented immigration since this time, which appears to have escalated since 2021.
UN Habitat III conference on Urban Sustainable Development – The New Urban Agenda
“Habitat III” [7] is shorthand for a major global summit, formally known as the United Nations Conference on Housing and Sustainable Urban Development, held in Quito, Ecuador, on 17-20 October 2016. [1, 2]
The United Nations called the conference, the third in a series that began in 1976 (UN Habitat), to “reinvigorate” the global political commitment to urban sustainable development goals. The agenda will set a new global strategy around urbanization for the next two decades – The New Urban Agenda.
- Habitat I (1976): Vancouver Declaration on Human Settlements – Vancouver, Canada, May 31 – June 11, 1976 [5]
- Habitat II (1996): Istanbul Declaration on Human Settlements – Istanbul, Turkey June 3-14, 1996 [3, 6]
- Habitat III (2016): Ecuador – Declaration of “The New Urban Agenda”
Starting in 1972 it was recognised that privately owned land was a threat to social equity on the planet, including ownership of “self”! [4]
Since 1985 the United Nations designated the first Monday of October of every year as World Habitat Day “to reflect on the state of our towns and cities, and on the basic right of all to adequate shelter.”
Google’s censorship machine ramps up
Following Donald Trump’s presidential win the November 2016 US election, the Google “censorship machine” , was set into action as exposed by Google Whistleblower, Zach Vorhies, on August 14, 2019 to Project Veritas.
In Google’s IPO they stated “Our company mission is to organize the world’s information and make it universally accessible and useful.”
From 2016, censorship became [secretly] part their Google’s model. By 2020 they openly confirm they will delete pandemic “misinformation” content that is counter to the narrative demanded by “authorities”.
WHO Emergency Response Framework
WHO released Second Edition of their Emergency Response Framework (ERF), (first 2013), to clarify and articulate WHO’s role and obligations under the International Health Regulations (2005). ERF places ultimate authority for WHO’s work in emergencies with the Director-General, but accountability and response speeds are delegated to Regional Dierctors and the WHE (est 2016) Executive Director.
Gain of Function moratorium set to be lifted
Just before the Inauguration of Donald Trump as President, on January 9, 2017 the Obama White House Office of Science and Technology Policy (OSTP) under the direction of John Holdren, announced policy guideline recommendations that “will satisfy the requirements for lifting the current moratorium on certain life sciences research [gain of function] that could enhance a pathogen’s virulence and/or transmissibility to produce a potential pandemic pathogen (an enhanced PPP).” [1]
These P3CO guidelines were adopted by December 19, 2017, and gain of function resumed – following committee review.
As pointed out by The Highwire, in 1977, John Holdren [2, 3] coauthored the book Ecoscience that discusses the concept of sterilisation as a form of population control, but more alarming is the statement: “Biological warfare laboratories are potential sources of a man-made “solution” to the population explosion.”
Holdren’s co-author is population “alarmist” [4] Paul Ehrlich, who in 1969 published The Population Bomb , which argued to halt population growth predicting people would starve to death years ago – a failed prediction. In January 2023 Ehrlich returns as an “environmental authority” to “revive his argument that current levels of human consumption” is not sustainable and “will lead to the mass extinction of plants, animals, and mankind itself”.
Dr Fauci warned of a “Surprise Outbreak” during the Trump administration
On January 10, 2017, at the Georgetown Global Health Initiative, Dr Anthony Fauci delivered his Keynote Address titled Pandemic Preparedness in the Next Administration where he said:
“There is no question that there will be a challenge to the coming administration in the arena of infectious diseases...but also there will be a surprise outbreak” [1, 2]
Ten days later was the inauguration of Donald J. Trump as President of the United States.
DARPA prepares for Pandemic X. Funds Moderna’s Phase 1 mRNA “vaccine” trials
On January 12, 2017 Moderna, with US Defense Advanced Research Projects Agency (DARPA) funding, began Phase I clinical trials of mRNA-1325 (a Zika vaccine) and was cleared to begin trials of mRNA-1388 (a Chikungunya vaccine). [1]
The following month, DARPA launched the “Pandemic Prevention Platform (P3) program, aimed at developing that foundational work into an entire system capable of halting the spread of any viral disease outbreak before it can escalate to pandemic status.” This stated intention of end-to-end vaccine platform, or medical countermeasure, is aimed to stop Pandemic X from taking hold, which appears other defense agencies, the Medical Counter Measures Consortium bought into the idea. [2]
“P3 focuses on rapid discovery, characterization, production, testing, and delivery of efficacious DNA- and RNA-encoded medical countermeasures, a foundational technology pioneered by DARPA under the ADEPT program”
““DARPA’s goal is to create a technology platform that can place a protective treatment into health providers’ hands within 60 days of a pathogen being identified, and have that treatment induce protection in patients within three days of administration.” DARPA believe that these nucleic-acid-based platform apporach for limiting the spread of infection, and would not “integrate into an individual’s genome” and the protein that the bodies cells are forced to make (in this case an antibody not antigen) would only last for “weeks to months“.
FDA publish EUA guidance – condition of EUA “no alternatives” can be available
On January 13, 2017 following a PAHPRA amendment the FDA issued guidance for industry and stakeholders around Emergency Use Authorisation (EUA) of Medical Products.
It states in guidance, section B.1.d titled “no alternatives” that “[f]or FDA to issue an EUA, there must be no adequate, approved, and available alternative to the candidate product for diagnosing, preventing, or treating the disease or condition”
For COVID-19 vaccines to be eligible for EUA, the system had to discredit and suppress any early treatment options such as hydroxychloroquine and ivermectin. [1]
“Public health was built on an obsessive global vaccination policy, which ivermectin would have threatened”
says Dr Pierre Kory
UN holds first World Data Forum – launching “Sustainable Development Data”
The United Nations convened the first World Data Forum (UNWDF) in Cape Town, South Africa on January 15-18, 2017, which has become an annual event. At the conclusion of the first event, “the Cape Town Global Action Plan for Sustainable Development Data was launched” [1, 2, 3, 6]
“The Forum was organized with the guidance of the UN Statistical Commission and the support of the UN Statistics Division of the UN Department of Economic and Social Affairs (DESA) and the High-level Group for Partnership, Coordination and Capacity-Building for statistics for the 2030 Agenda for Sustainable Development (HLG).”
This platform was used “for intensifying cooperation with various professional groups, such as national statistical offices (NSOs), information technology and geospatial information managers, and data scientists among other representatives of government, intergovernmental organizations and civil society.” [4] With “particular focus on addressing the monitoring needs of the 2030 Agenda”
“The decision to organize a series of UN World Data Forums followed a recommendation in the report titled, “A World That Counts: Mobilising the Data Revolution for Sustainable Development,” [6] which was presented in November 2014 by the UN Secretary-General’s Independent Expert Advisory Group on a Data Revolution for Sustainable Development” [5]
On day three in the session titled ““Capturing the 21st Century through Data and Algorithms.” Speakers emphasized that the public’s world view and knowledge do not mirror reality, and suggested that schools are better places to create a more fact-based world view than the media; emphasized the value of building narratives from data to steer the narrative to implement the SDGs…”
CEPI is launched
The Coalition for Epidemic Preparedness and Innovations (CEPI) was officially launched at the World Economic Forum (WEF) in Davos, Switzerland on January 18 2017, “in response to expert reports into the 2013-16 Ebola outbreak, calling for a new system to stimulate vaccine development based on collective action and partnerships across sectors and countries”.
The are stated to be “a new alliance to finance and coordinate the development of new vaccines to prevent and contain infectious disease epidemics”. It is structured as a “global coalition to create new vaccines for emerging infectious diseases” “for which no vaccines have been created” and prepare for “Disease X.”
CEPI is a public-private collaboration with it founding partners the governments of Germany, Japan, Norway and India, the B&M Gates Foundation and the Wellcome Trust, plus Pharma companies: GSK, Pfizer, J&J, Merck & Sanofi. The Chairperson of CEPI is Australia’s Jane Halton [1, 2]
CEPI is instrumental in the COVAX vaccine rollout, plus formed a partnership with CSL and University of Queensland to bring COVID-19 vaccine to market.
On September 5, 2020, just 9 months after launch they put a call out for proposals for vaccines that can reduce development time.
Donald J. Trump’s Inauguration as the 45th President of The United States of America
On January 20, 2017 Donald J. Trump was sworn in as the 45th President of the United States of America. On that inauguration day Trump delivered a powerful speech.
Ten days earlier and Jan 10th, Dr Anthony Fauci delivered his keynote speech to the Georgetown Global Health Initiative, stating during the next administration (Trump’s) they WOULD experience an infectious disease “surprise outbreak“.
Fast forward SARS-CoV-2 outbreak likely from a lab in China
Bill Gates’ “prophecy” at Munich Security Conference – CEPI: to enable a vaccine in 90 days or less
“Prophetic” quotes from Bill Gates speech [1] at the Munich Security Conference on February 17, 2017 , setting the stage f:
“I decided 20 years ago to make global health the focus of my philanthropic work”…I spend a lot of my time on the effort to eradicate polio…
It’s also true that the next epidemic could originate on the computer screen of a terrorist intent on using genetic engineering to create a synthetic version of the smallpox virus . . . or a super contagious and deadly strain of the flu….The point is, we ignore the link between health security and international security at our peril.
The good news is that with advances in biotechnology, new vaccines and drugs can help prevent epidemics from spreading out of control.
Vaccines can be especially important in containing epidemics. But today, it typically takes up to 10 years to develop and license a new vaccine. To significantly curb deaths from a fast-moving airborne pathogen, we would have to get that down considerably—to 90 days or less.
We took an important step last month with the launch of a new public-private partnership called the Coalition for Epidemic Preparedness Innovations (CEPI). The hope is that CEPI will enable the world to produce safe, effective vaccines as quickly as new threats emerge.
The really big breakthrough potential is in emerging technology platforms that leverage recent advances in genomics to dramatically reduce the time needed to develop vaccines… synthetic genetic material that instructs your cells to make a vaccine inside your own body. And the great thing is that once you’ve built a vaccine platform for one pathogen, you can use it again for other pathogens. You only need to substitute a few genes.
The third thing we need to do is prepare for epidemics the way the military prepares for war.
It is encouraging that global alliances like the G7 and the G20 are beginning to focus on pandemic preparedness…
Pandemics are everyone’s problem—and as leaders, we cannot ignore it.
…we face today with biological threats. We may not know if that weapon is man-made or a product of nature. But one thing we can be almost certain of. A highly lethal global pandemic will occur in our lifetimes.
I view the threat of deadly pandemics right up there with nuclear war and climate change.
AAP/IAC are “challenged” by Trump’s vaccine safety concerns
On April 13, 2017 the American Academy of Pediatrics (AAP) attended an Immunization Action Coalition (IAC) webinar titled “Vaccine Challenges in a New Administration“. Their presentation slides show their “alarm and disdain” about President Donald Trump’s vaccine safety concerns and they singled out Robert F. Kennedy Jr. (RFK jr) [1, 3]
They knew that Trump was “not beholden to the pharmaceutical industry” as he didn’t accept funding to get him elected in 2016 [though did for his inauguration], and that he has a history of expressing concerns regarding the regressive health trends in children relative to the increasing vaccine trends.
AAP noted on January 10, 2017 that RFK jr met with President-elect Trump at Trump Tower where Kennedy was asked to chair a new commission on “vaccine safety and scientific integrity”, allegedly focused on “autism”. That same day AAP issues a statement declaring “vaccines are safe, vaccines are effective, vaccines save lives“. [2]
At a Feb. 15, 2017 – Press Conference with Robert De Niro and RFK jr before a congressional briefing the next day which was “sparsely attended”, RFK jr offered $100K reward to the “first journalist, or other individual, who can find a peer-reviewed scientific study demonstrating that thimerosal is safe in the amounts contained in vaccines currently being administered to American children and pregnant women.”
What they didn’t note was in late 2016 Trump did accepted millions in donations from pharmaceutical giants like Pfizer, for his inauguration celebrations. [4] Shortly after Trump appointed pharma connected Scott Gottlieb (March 2017) to head the FDA and then Alex Azar (Nov 2017) as secretary of HHS. RFK jr has said these two were “hand picked by Pfizer”[?] and they “killed the vaccine safety commission”!
Then over 4 days in March 2018, RFK, Jr. and 15 other advocates presented “Six Steps to Vaccine Safety” to every member of Congress, detaining the steep increase in childhood chronic illness and the actions necessary to introduce sound science and transparency to the US vaccination program. [11, 12]
The Immunization Action Coalition is a 501(c)(3) [9] non-profit founded by Deborah L Wexler, MD with a newsletter from 1990, because of a measles outbreak. By Feb 1994 they ran out of money but by June 1994 Wexler received a $100K grant from Hep B vaccine maker Smith-Kline Beecham.
By September 1994 the newsletter “expanded to include all immunizations and the organization’s name was changed from the Hepatitis B Coalition to the Immunization Action Coalition to reflect the shift. The newsletter’s title also was changed to “Needle Tips & the Hepatitis B Coalition News.”[13]
On August 30, 1995 Wexler won a funding boost of $750K from the CDC, as well as their “prized mailing list of 14,000 health care professionals”! Wexler now promotes for the CDC.
By 2021, Chief Strategy Officer, Litjen Tan MS PhD, pushes for adult immunizations. [5, 6, 7, 8, 9, 10]
Moderna: First-in-human Influenza mRNA vaccine study
In an April 27, 2017 press release the first human proof-of-concept data from Moderna’s mRNA technology platform was released. “In addition, they are the first-ever published data demonstrating a prophylactic mRNA vaccine’s ability to elicit robust immunity in humans”. Moderna distinguishes a “mRNA Therapeutic” from an “mRNA Vaccine” simply by the intent of the protein code, that being to “fight disease” versus “prevent disease”.
In a Cell paper, funded by Moderna Therapeutics, looking at the “immunogenicity by mRNA Vaccines” against H10N8 (mRNA-1440) and H7N9 (mRNA-1851) Influenza Viruses. They concluded that “LNP-formulated, modified mRNA vaccines can induce protective immunogenicity with acceptable tolerability profiles” in mouse studies and a First-in-Human Phase 1 Study with 31 human subjects (23 of whom received mRNA-1440 and eight of whom received placebo) and were followed for only 43 days, but the intent is for subjects to be “followed for up to 1 year post-vaccination for safety and immunogenicity”. [1, 2, 3]
“mRNA-1440 demonstrated strong efficacy based on Hemagglutination Inhibition Assay (HAI) and Microneutralization Assay (MN) titers, two measures of immunogenicity in response to vaccination.” Achieving antibody “titers consistent with protection at day 43.”
- Clinical trials (NCT03076385 ) began March 2, 2017
- “Adverse events (AEs) according to FDA scale were mild or moderate with 3 subjects (13%) experiencing severe adverse events, it “demonstrated a safety profile consistent with that of approved vaccines”. [4, 5]
- Until recently mRNA vaccines were not advanced into the clinic due to concerns around stability and production.
The paper states that mRNA vaccines “offer advantages in speed, precision, adaptability of antigen design and production control that cannot be replicated with conventional platforms,” and that until recently mRNA vaccines “were not advanced into the clinic due to concerns around stability and production.”
But now with the ever looming “concern for a potential pandemic and the need for an effective, safe, and high-speed, and scalable vaccine production platform, the mRNA-based vaccines make them ideally suited to impede potential pandemic threats.”
First G20 Health Ministers – MARS pandemic simulation
Each year G20 Presidancy is allocated to a new country, on December 1, 2016 Germany was awarded the role, which during it’s G20 Presidency the German Government, led by Angela Merkel, leveraged “health” for the first time on G20 agendas by creating the Health Ministers track.
On May 19-20, 2017, at the invitation of Federal Minister of Health Hermann Gröhe, the first G20 Health Ministers meeting took place in Berlin, Germany. The purpose to focus on combating global health hazards and be better prepared for future health crises such as pandemics.
At that meeting the participants participated in a respiratory virus pandemic health emergency simulation called MARS (Mountain Associated Respiratory Syndrome). The exercise focused on multilateral coordination, with WHO’s crisis response mechanisms and the International Health Regulations (IHR). This meeting marks the start of “Global Health” becoming a constant on the G20 agenda.
Following this 2017 meeting The Center for Global Health was founded in by Prof. Andrea Winkler and Prof. Clarissa Prazeres da Costa. Germany is leading the way with global health policy, their “goal is that research results are quickly translated into meaningful and effective political measures. This is the only way we can achieve the goals for sustainable development of the United Nations, to which the Federal Republic of Germany has also committed itself.” [1]
“Due to the increasing interconnectedness of our world, health has also become an issue that needs to be viewed globally.”
In 2016 China held last G20 meeting, which “laid the foundations” for “anchoring the topic of international health in the communiqué of the Heads of State and Government for the first time”. In her opening statement, Merkel even mentioned the 1918 Spanish flu! [2]
NIAID convenes Universal Flu Vaccine workshop
In June 28-29, 2017 the NIAID convened a workshop in Rockville, Maryland titled “Pathway to a Universal Influenza Vaccine“, which was attended by 150 scientists from academia, industry, and government from around the world to develop criteria for defining a universal influenza vaccine, one “that would cover most or all seasonal strains of influenza, and also provide protection during a pandemic”
The workshop findings, jointly authored with Dr Anthony Fauci weere published in the journal Immunity on October 17, 2017, outlining four key criteria that a universal vaccine should meet. [1, 2]
From this publication the NIAID’s strategic plan for developing a universal influenza vaccine emerged in February 28, 2018, followed by the creation of the Collaborative Influenza Vaccine Innovation Centers (CIVICs) center in 2019.
G20 Berlin Declaration
At the July 7-8, 2017 G20 Summit, the Berlin Declaration “Together Today for a Healthy Tomorrow” was declared with “seven-page final resolution on pandemic preparedness and antimicrobial resistance.” [1, 2, 3]
Global health , to “leave no one behind”, is top of the G20 agenda.
On June 28, 2017 a coalition of “33 leading Global Health organisations and members of National Parliaments have issued an open letter to G20 Heads of State, to prioritise health and establish the G20 as a permanent global health policy forum. With a Call to Action strongly urging the G20 to commit investment in research, innovation and development of innovative health technologies to counter threats posed by pandemics, poverty related disese and more. [6, 7]
And so was formed the G20 Health Development Parnership (G20HDP) with the mission “to mobilise, through political, intellectual, social and economic capital, the means required to meet Agenda 2030”. [4, 5]
WHO release SDG Health Price Tag
“The SDG Health Price Tag, published July 17, 2017 in The Lancet Global Health, estimates the costs and benefits of progressively expanding health services in order to reach 16 Sustainable Development Goal (SDG) health targets in 67 low- and middle-income countries that account for 75% of the world’s population. [2]
The analysis shows that investments to expand services towards WHO’s priority goal of universal health coverage and the other SDG health targets could prevent 97 million premature deaths globally between now [2017] and 2030, and add as much as 8.4 years of life expectancy in some countries…. the poorest nations will need assistance to reach the targets.”
Under the “ambitious” scenario, achieving the SDG health targets would require new investments increasing over time from an initial US$ 134 billion annually to $371 billion, or $58 per person, by 2030. …As many as 32 of the world’s poorest countries will face an annual gap of up to US$ 54 billion and will continue to need external assistance.
The ambitious scenario includes adding more than 23 million health workers, and building more than 415 000 new health facilities, 91% of which would be primary health care centres.
Promotional WHO info Graphics [1]
CEPI push for a rapid, new vaccine platform
On September 5, 2017, just 9 months after the launch of CEPI, they put a call out for proposals with the aim to identify new vaccine platform technologies that would enable rapid vaccine development, elicit rapid onset of immunity, and whose production can be scaled-up quickly to respond to the next pandemic disease, soon to be called Disease X. Funding from B&M Gates Foundation and NIAID.
On October 15, 2019 , CEPI launches a “new call for innovative platform technologies to rapidly respond to Disease X” on the back of the September 2019 GPMB “A World At Risk” report!
TGA adds Black Triangle Scheme for drug and vaccine adverse event reporting
On October 12, 2017 the Therapeutic Goods Administration (TGA) added the Black Triangle Scheme (BTS) to their safety monitoring system. [1, 2]. “A similar Black Triangle Scheme currently operates throughout the member states of the European Union, including the UK.”
Five months before Provisional Registration which is added to the Therapeutics Goods Act in March 2018. All new and Provisionally Registered (PR) products fall under the BTS to help monitor for early safety signals. Product Inserts (PI) and Consumer Medicines Information (CMI) are indicated with a black triangle symbol [2, 3] which will appear for a period of not less than five years from start of PR. Sponsors are responsible to supply information for PI and CMI documents.
An adverse event is definded as “any unfavourable and unintended sign, symptom or disease associated with the use of ” the provisionally registered product and all “should be reported” by either consumers but most importantly health professionals, although the TGA don’t openly share this advice for COVID-19 vaccine products.
All 2021 COVID-19 vaccines were only Provisionally Registratered, which is distinctly different to Registered. [4]
United Kingdom’s drug regulator MHRA also has a Black Triangle Scheme, for continued monitoring of medicines, which appears to have been in place since June 1, 2009. [5] The European Medicines Agency (EMA) in 2017 was responsible for maintaining the list of black triangle products which included AstraZeneca, Moderna, BioNTech, Janssen COVID-19 vaccines.
It seems Black Triangle Scheme is not unique to Australia, but infact a global regulatory practice which the TGA adopted.
SPARS Coronavirus Scenario
On October 23, 2017 The Johns Hopkins Center for Health Security released the SPARS Scenario, a pandemic simulation event, portraying a futureistic scenario for public health risk communicators, where a new virus infects mankind in 2025 and continues until 2028. The self-guided tabletop training experience challenged public health communicators and risk communication researchers to consider the complex messaging dilemmas of a future outbreak, which required the development of a new vaccine. [1, 2]
The fictitious outbreak of the novel SPARS coronavirus is first identified in a major US city in 2025, over 3 years it spreads world wide and the case fatality rates vary depending on the capabilities of local health systems.
Moderna’s first in-human “cancer vaccine” dosed
On November 15, 2017 Moderna in collaboration with Merck (product and $200M funding) announced their first-in-human dosing of their KEYNOTE-603 Phase 1 clinical trial using mRNA-4157, and mRNA gene therapy product which they refered to as a “personaised cancer vaccine“. [1, 2]
Children are labelled “super spreaders”- get the flu-jab to protect grandma!
In a November 27, 2017 article, the UK calls for parent to get their ‘super spreader’ children in daycare, vaccinated with a free flu jab so that they “protect” their grandparents from the risk of the flu!
The vaccines are simply “assumed” to be safe and effective, yet the CDC state that influenza vaccines are only 40-60% effective, but in some years is as low as 10%! So what is the real benefit, and at what risk both short and long-term?
It would seem most people don’t realise that influenza & pneumonia statistics are lumped together and advertised as deaths due to flu – its a “death certificate” conundrum. Flu estimates are based on ever changing models such as Canada’s estimate flu deaths going from 500/yr to 8000/yr. Every year there are many influenza-like-illness (ILI) which is generally called the flu, but is this yearly flu jabbing actually making things worse? [@45:50] [1]
Doctors are educated by marketers to increase flu-shot demand. So is this really about health, protection or big-pharma money!
Chinese chimeric research funded by NIH
Published November 30, 2017, research in at the Wuhan Institute of Virology, that was funded by US NIH showed man-made (chimeric) viruses could replicate in human cells.
Dr Anthony Fauci and Dr Francis Collins claimed is not Gain of Function research, but Dr Fauci, in his own words, says it is! [1, 2, 3]
Fauci supported review paper sets the stage for pandemic “prototype vaccines”
In a private meeting in February 2017, Dr Barney Graham pitched his “brainchild” Prototype Vaccine Project to the NIAID executives which included Dr. Fauci who said the idea struck him and others in the executive committee “as something that is really doable.”
Following that meeting, on December 14, 2017, Dr Graham published a review paper outlining the proposal in Nature Immunology titled “Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic“, in which Fauci provided “editorial comments” and the NIAID supported. This paper sets the stage for moving forward with “prototype vaccines” for all pathogens with pandemic potential!
The paper stated “developing rational candidate vaccines directed against at least one prototype virus within each major phenotypic category within each family of viruses is advisable”
The paper concluded that “[p]reparation for emerging viral disease will be an inherent component of achieving the United Nations Sustainable Development Goals (UN SDG)”
“But without the urgency of a threatening pandemic, his [Dr Graham‘s] idea remained just that.” stated the New York Times on July 25, 2021, as Fauci seeks funding the “brainchild” project!
HHS lifts ban on Gain-of-Function research – P3CO Framework established
On January 9, 2017 the White House Office of Science and Technology Policy (OSTP) released their “Recommended Policy Guidance for Departmental Development of Review Mechanisms for Potential Pandemic Pathogen Care and Oversight (P3CO).” Noting “[a]doption of these recommendations will satisfy the requirements for lifting the current moratorium on certain life sciences research that could enhance a pathogen’s virulence and/or transmissibility to produce a potential pandemic pathogen (an enhanced PPP).”
By the end of that year, on December 19, 2017, Francis Collins, Director of US National Institute of Health (NIH) announced it was lifting the October 16, 2014 funding moratorium [9, 10] on Gain-of-Function (GoF) research. [6] “Dual Use” research continued because HHS adopted the pre-funding review mechanism called the Potential Pandemic Pathogen Care and Oversight (P3CO) Framework which would be used to make funding decisions for GoF-type research. [1, 20]
How this came about:
Starting late 2014, the National Science Advisory Board for Biosecurity (NSABB) who served as the “official federal advisory body on GoF research issues and is responsible for developing recommendations for the appropriate level of Federal oversight of GoF research”. Which was infomed by Gryphon Scientific, who were “contracted by the NIH Office of Science Policy [OSTP] to conduct risk and benefit assessments (RBA) of GoF research involving the pathogens subject to the funding pause.” NSABB worked in conjunction with the National Academies of Sciences. [18]
Following less than 3 years (2014-2016) of NSABB symposiums, together with Gryphon Scientific reports, two report were published:
- May 2015 the NSABB recommended Framework for Conducting Risk and Benefit Assessments of Gain-of-Function Research
- May 2016 the NSABB final report titled Recommendations for the evaluation and oversight of proposed Gain-of-Function research which Section 6 included “a more rigorous description of GOF research of concern (GOFROC).” [2, 14]
On January 9, 2017, just before the Inauguration of Donald Trump as President, the Obama White House OSTP released their recommended policy guidance for the Department of Health and Human Services (HHS) to develop a GoF research assessment framework based on the NSABB recommendations. [3, 4]
By December 2017 the HHS adopted the pre-funding guidance mechanism called the Potential Pandemic Pathogen Care and Oversight (P3CO). Under the HHS P3CO Framework, the HHS P3CO Review Group [11] make funding decisions for enhanced PPP/GoF research projects. [5, 6] The review group approved example A & B. [12]
By February 2022 at a NSABB meeting, the NIH show slides with revised definitions of GoF research; either “Dual Use Research Of Concern (DURC)” or emerging pandemic potential pathogens “ePPP‘s”. [7, 8]
Working in conjuction with NSABB, the The National Academies of Sciences held two Gain of Function Symposiums (Dec. 15-16, 2014 [17] & Mar. 10-22, 2016). Participating in these symposiums were:
- Philip Dormitzer [15, 19, 21] who went from Novatis Vaccines (2014) then to VP & Chief Scientific Officer of Pfizer‘s Viral Vaccines,
- China’s CDC director George Gao
- Ralph Baric on the topic “vaccines targeting coronaviruses”
- Prof Ian Lipkin 2014 [16, 17]
DARPA launches PREEMPT program
On January 4, 2018 DARPA announces their new 3.5-year “program called Preventing Emerging Pathogenic Threats, or PREEMPT, seeks to support military readiness by going after new viral infectious diseases at the source, animal reservoirs—the species in which a pathogen lives, multiplies, and potentially evolves into a strain that can threaten humans.”
In February 2019 DARPA announced their partnership with 5 companies who are developing new generation countermeasure platforms, includes Autonomous Therapeutics who has as self-spreading vaccine conceived in 2014 and accelerating in 2024. [1, 2]
Promoted as a “New Layer of Medical Preparedness to Combat Emerging Infectious Disease” where industry research “supporting PREEMPT program will model viral evolution in animal populations, quantify the probability of human pathogen emergence, and pursue proof-of-concept interventions to prevent viral spread to humans”.
Concerns raised about safety protocols at the China, Wuhan biosecurity lab
In a cable dated January 19, 2018, SU delegates paid multiple visits to China’s Wuhan level 4 biosecurity lab and reported to Washington that a lack of safety protocols could spark a SARS-like outbreak. [1]
As lab security is a now known issue, a credible investigation into the 2020 origins of the SARS-CoV-2 virus is needed.
ACIP vaccine approval process
Cameras capture key moments in 2018 CDC Advisory Committee on Immunisation Practices (ACIP) meeting as they suprisingly vote to approve a new vaccine with a brand new adjuvant that has known potential issues.
Reminder, Australian doctors refers to CDC for guidance on vaccine administration, and the TGA collaborate with international regulators.
The term “Disease X” is born – the next unknown pandemic
At a annual WHO R&D Blueprint meeting held February 6-7, 2018, “a group of experts” which Peter Daszak belongs to coined the term “Disease X”. They were “referring to the next pandemic, which would be caused by an unknown, novel pathogen that hadn’t yet entered the human population.” and of which there was an “absence of efficacious drugs and/or vaccines”. [1]
The objective of the blueprint and meeting was “to reduce the time between declaration of a public health emergency and the availability of effective diagnostic tests, vaccines, antivirals and other treatments that can save lives and avert a public health crisis”
Disease X would likely:
- Result from a virus originating in animals and would emerge somewhere on the planet where economic development drives people and wildlife together.
- Be confused with other diseases early in the outbreak and would spread quickly and silently; exploiting networks of human travel and trade, it would reach multiple countries and thwart containment.
- Have a mortality rate higher than a seasonal flu but would spread as easily as the flu.
- It would shake financial markets even before it achieved pandemic status.
On October 15, 2019, “CEPI launches new call for innovative platform technologies to rapidly respond to Disease X”, their first call for fast new vaccine platforms went out in 2017.
At Davos 2024 the WEF “preparing for Disease X” with “disinformation” threatens! [2, 3].
NIAID release their Strategic Plan for a Universal Flu Vaccine
On February 28, 2018, the NIAID led by Dr Fauci, published their strategic plan for developing a universal influenza vaccine, which was the result of a June 2017 NIAID workshop. [1, 2]
The following by year in 2019 the NIAID created the Collaborative Influenza Vaccine Innovation Centers (CIVICs), out of needs identified in the NIAID Universal Influenza Vaccine Strategic Plan.
TGA legislations change sets up for Vaccine advertising
On March 6, 2018, clause 42DK(3) was added to the Therapeutic Goods Act 1989 which sets the stage for future product advertising (vaccines) by an Australian state, when it is in the interest of “public health”. [1, 2]
In Australia advertising of pharmaceuticals on television has been prohibited, but this new clause sets the stage for the TGA to allow Health Departments to advertise vaccines on behalf of manufacturers direct to the public.
Global Disinformation Index non-profit is established to rate “risk” of media sites
The self appointed, Global Disinformation Index (GDI) non-profit organisation launched its website around March 11, 2018, but registerd but incorprated the UK-based entity on April 7, 2018. It established 2 affiliates in the use in Nov. 2018 and Sept. 2020 respectively. Their stated mission is to “Restore trust in the media by providing real-time automated risk ratings of the world’s media sites through a Global Disinformation Index.” [1, 2]
Their “Prototype Funding” round closing April 30, 2018, and by 2019 they were supported by: Knight Foundation, USAID, Luminate, the UK Foreign & Commonwealth Office and Article 19 [3, 4, 5, 6] Luminate was established in 2018 by philanthropists Pierre and Pam Omidyar, and curiously in 2017 they partnered with Knight Foundation to “research artificial intelligence for the public interest”.
The archives lists the co-founders as:
- Alexandra Mousavizadeh – CEO of Decima Global [an obsucure company, that doesn’ really exist, and is not mentioned in her LinkedIn]
- Clare Melford of 9 Degrees and former managing director of MTV Network
- Miguel Martinez – Chief Data Scientist, Signal – REF
- Dr. Daniel Rogers of Terbium Labs & Veracity.ai (He appears to be added as co-founder in June 2018)
In October 2018, Mousavizadeh was a speaker at the second United Nations World Data Forum in Dubai.
On April 13, 2021 The GDI submitted a report to the United Nations 47th session of the Human Rights Council, who called for “Reports on Disinformation” – where they state the “GDI’s goal is to catalyse industry to reduce disinformation and its harms by going after the financial incentives to create disinformation….primarily by primarily by seeking to defund disinformation – breaking the incentive to
create it for the purpose of garnering advertising revenues…” [Disinformation Resolution passed at the 66th UN GA January 2022]
UNESCO state “GDI provides disinformation risk ratings for news sites in media markets around the globe.” Who’s risk ratings are neutral, independent and transparent”, but conservative media appear to be their target and they maybe violating the law. [7]
Provisional Registration added to TGA legislation
On March 29, 2018 the Australian government added a Provisional Registration (PR) amendment to the Therapeutic Goods Act (1989), of which the TGA Secretary now has overriding power to send a product application through the registration process with only preliminary clinical data. [3]
This decision was publicised on June 26, 2017 as a “Priority review pathway for the registration of novel prescription medicines for Australian patients….[and] will involve faster assessment of vital and life-saving prescription medicines”. With specific eligibility criteria, including no existing alternative products.
The intent of this new registration category was explained in parliament in September of 2017 by Mr Greg Hunt as being intended as an avenue to provide “medicine” to those people with “significant unmet clinical needs for serious conditions”. [8, 9]
The process started October 24, 2014 with the announcment of the MMDR panel of 3 experts to review and report on the regulatory framework of therapeutic goods. [4, 5, 6, 7] The panel recomended a provisional pathway. [13, 14]
The government responded in 2016, noting the “international trends towards allowing earlier access to medicines” especially looking to fast-track “novel and life–saving medicines”, with a seeming emphasis on cancer drugs. [10]
- Provisional registrations are of a limited duration (max 2 years) and require the sponsor to supply ongoing clinical data to support their product.
- All PR products are part of the Black Triangle Scheme where healthcare professionals or consumers should report to the TGA all and any “any unfavourable and unintended sign, symptom or disease” following the use of the product “to help us build up the full picture of a medicine’s safety profile.” It’s not the doctor’s job to determine if a unintended consequence is related or not to the medicine.
- “For provisionally-registered medicines, the black triangle symbol will appear for a period of not less than five years.””
- Such “registrations” are added to the Australian Register of Therapeutic Goods (ARTG), but they are not classed as fully registered, they are still under assessment and may never receive full registration status.
Between 1 April 2018 until 22 June 2021 there has been [12] Provisional Registrations of which 2 are COVID-19 vaccines [1, 2] and 1 is remdesivir.
100 years since 1918 “Spanish Flu” pandemic – GOF research promoted
In a symposium marking 100 years since 1918 “Spanish Flu” pandemic, Professor Ralph Baric from UNC-Chapel Hill, speaks to the necessity of Gain of Function (GOF) research, and the opportunities to available from pandemics.
Ralph Baric is a “longtime collaborator” with Shi Zheng-Li (the “Bat Lady”) of the bat coronavirus research lab in Wuhan.
Paper: Use of Novel Vaccine Technologies for Emerging Viral Diseases
On April 10, 2018, Dr Anthony Fauci co-authors a viewpoint paper in JAMA Network setting the stage for novel genetic vaccines (mRNA or DNA) to shorten the time “to design, manufacture, and evaluate vaccines for clinical use…in response to newly emerging infections”.
“The time-honored approach to vaccinology,… has not adequately met” the challenge of “emerging viral diseases with pandemic potential.” So this paper looks to “exploit modern-day technological advances.”
[Reading this paper in retrospect summarises the “vaccine solution” response to Pandemic 2020.]
“Historically, the process of vaccine development through to licensure requires decades…[i]n total, 15 to 20 years would be a typical timeframe from virus discovery to vaccine availability if the process proceeds smoothly and there are no major biological or logistical challenges.”
…[H]owever, clinicians and public health officials are often faced with outbreaks of viral diseases, sometimes of a pandemic nature that would require vaccines for adequate control.”
“Rapid genetic sequencing allows both early identification of new pathogens and the identity of the genes encoding structural proteins that can form the basis for vaccine immunogen development.”
“Synthetic vaccinology and platform manufacturing are important innovations that can speed the initial vaccine immunogen design and vaccine development process, and shorten the time needed for manufacturing and initial regulatory approval to begin phase 1 testing.”
“The process of gene synthesis is now extremely rapid…[t]hese genetic vectors (DNA and mRNA) can be used directly for immunization whereby intramuscular immunization leads to muscle cells producing the viral proteins. Alternatively, the genetic vectors can be used to express recombinant protein antigens, in vitro, that can be used for immunization.”
“The term platform …in vaccine production… implies that the method for generating and presenting a vaccine immunogen can be applied across multiple pathogens.” “DNA or mRNA nucleic acid vaccines are good examples of how platform manufacturing can shorten timelines from pathogen identification to phase 1 clinical trials.” [1, 2]
“DNA vaccine delivery and immunogenicity have evolved and improved over the last 2 decades, making it a viable platform for vaccination.”
Based on NIAID experience “Once these pathogens were identified, the time from viral sequence selection to initiation of the phase 1 clinical trial was shortened from 20 months to slightly longer than 3 months.”
“Traditional approaches, such as live-attenuated virus vaccines (eg, Sabin polio) or whole-inactivated virus vaccines (eg, Salk polio) would not qualify as platform approaches because the requirements for growth in cell culture and purification are usually different among virus families. Protein-based approaches … may not be amenable to platform approaches.”
“Having a standard manufacturing approach reduces the time needed for current Good Manufacturing Procedures process development and simplifies regulatory approval because the safety database that has accumulated for a given platform can be applied to multiple vaccine products.”
Dr Fauci published another paper on “novel vaccine technologies” in Nature in November 2019…all in time for pandemic 2020.
mRNA vaccines are still in “preclinical studies” in September 2018.
WHO STAG-IG group began
On May 8-9, 2018, the WHO Health Emergencies (WHE) Programme led by Dr Mike Ryan, convened a meeting to prepare for the establishment of the Strategic and Technical Advisory Group for Infectious Hazards (STAG-IH), a multidisciplinary group of external experts newly tasked with advising the Deputy Director-General of Emergency Preparedness and Response on new and emerging infectious hazards that can threaten global health security. A program “ underpinned” by the International Health Regulations. The members of STAG-IH are chosen by the WHO Director-General, of which a current member include the Robert Koch Institute’s Prof Lothar Wieler.
COVID – 19 Meetings are here.
Clade X – US bio-terrorism Simulation
On May 15, 2018, hosted by the Johns Hopkins Center for Health Security and held in Washington, DC, high level officials participated in a day-long pandemic tabletop exercise called Clade X. [1, 2]
“Drawing from actual events, Clade X identifies important policy issues and preparedness challenges that could be solved with sufficient political will and attention.”
A fictional elitist cult had financed the creation of a deadly virus called “Clade X ” in a bio-lab in Zurich, with the aim of reducing the global population. A Global pandemic resulted upon it’s fictitious release.
“In the end, the outcome was tragic: the most catastrophic pandemic in history with hundreds of millions of deaths, economic collapse and societal upheaval” — Clade X pandemic simulation (May, 2018)
The simulation concluded that the world wasn’t prepared for a global pandemic.
Global Preparedness Monitoring Board Formed
Global Preparedness Monitoring Board (GPMB) was created in response to recommendations by the UN Secretary General’s Global Health Crises Task Force mid-2017.
The predecessor Global Health Crises Task Force was created in 2016 in response to the West Africa Ebola outbreak, they stated “Recent health emergencies, including the 2014-2016 West African Ebola outbreak, shed light on the major gaps in sustained political will, action, and sustainable financing for preparedness” and they recommended “the need for robust ongoing monitoring of global health emergency preparedness.”
The GPMB was formally launched in 24 May 2018, with their first meeting was held Sept 2018, the board is co-convened by the WHO and the World Bank Group and is said to be “an independent monitoring and accountability body to ensure preparedness for global health crises”, with funding that has come from the Gates Foundation, Wellcome Trust, & Germany. [1]
The GPMB commissions, prepares and “publishes an annual report on global preparedness for health emergencies that provides an authoritative assessment that is easily translatable to action for policymakers, researchers, health professionals and donors”. The September 2019 report “A World At Risk”.
In Sept 2019 the Johns Hopkins Center for Health Security release a timely report titled “Preparedness for a High-Impact Respiratory Pathogen Pandemic”, and then in September 2019 the GMPB release their complied report “A World At Risk”, a month later in October 2019 Event 201 was held.
The founding co-chair Dr Gro Harlem Brundtland, was (may still be) a member of the Trilateral Commission and wrote “Our Common Future“, the book that popularised the term Sustainable Development, and provided the framework for the UN Agenda 21 in 1992.
Many of the Board members have been intimately involved with steering the pandemic narrative:
- Co-Chair – Dr Gro Harlem Brundtland – Served as WHO Director-General 1998-2003
- Co-Chair – Mr Elhadj As Sy – Red Cross
- Dr Victor Dzau – President Nat. Acad. Medicine
- Dr Chris Elias – President B&M Gates Foundation
- Sir Jeremy Farrar – Director Wellcome Trust
- George F Gao – China’s CDC
- Dr Anthony S Fauci – Director of NIH
- H.E. Sigrid Kaag – Netherlands
- Prof Ilona Kickbusch – German/Switzerland
- Henrietta Fore – UNICEF
- Dr Yasuhiro Suzuki – Japan
- Prof Veronika Skvortsova – Russian Federation
- Prof K VijayRaghaven – India
Learn more >>
Bill Gates predicts a large and lethal pandemic in our lifetime
Bill Gates writes in a NEJM perspective on May 31, 2018, “Thanks to better vaccines” we’ve made headway on diseases.
“Yet there is one area where the world isn’t making much progress: pandemic preparedness. This failure should concern us all, because history has taught us there will be another deadly global pandemic. We can’t predict when, but given the continual emergence of new pathogens, the increasing risk of a bioterror attack, and the ever-increasing connectedness of our world [population growth] , there is a significant probability that a large and lethal modern-day pandemic will occur in our lifetime.”
“What the world needs is a coordinated global approach to pandemics that will work regardless of whether the next pandemic is a product of humans or of nature.”
The percentage of people who choose to get a seasonal influenza vaccine is fairly small, but modelling simulations suggest a “highly contagious and lethal airborne pathogen” could see “33 million people worldwide would die in just 6 months”.
[2 1/2 years into the COVID-19 pandemic 6.3 million deaths have been recorded worldwide]
On May 29, 2018 the Gates foundation “launched a $12 million Grand Challenge … to accelerate the development of a universal influenza vaccine” in order to end the “pandemic threat”. He noted “the current influenza vaccines significantly underperform.”
“However, the next threat may not be influenza at all.”
Late 2018 CEPI will award grants “to several companies, working with a variety of technologies, including nucleic acid vaccines, viral vectors, and other innovative approaches. The goal is the capability to develop, test, and release new vaccines in a matter of months rather than years.”
“If we can learn how to use RNA or gene delivery effectively, we may not need to make the antibodies at all. Instead, new methods of gene delivery could enable our own cells to produce these antibodies directly.”
“In the case of biologic threats, that sense of urgency is lacking.” The “world needs to prepare for pandemics in the same serious way it prepares for war.”
Merck launches RNA Particle (RP) Technology Vaccine Platform for Swine
On June 6, 2018 Merck Animal Health announced their new RNA Particle (RP) Technology Vaccine Platform first product targeting Pigs, called SEQUIVITY™ which they launched at the 2018 World Pork Expo. [1, 2, 3]
Sequivity™ RNA Particle Technology, is an alphavirus replicon vector system, where the platform allows for “Veterinary Prescription” or customised herd-specific “vaccines” [5]. “After receiving the sequence, it is synthesised into RNA and inserted into the SEQUIVITY platform, which generates RNA particles. When injected in the animal, these particles provide instructions to the immune cells to translate the sequence into proteins which act as antigens.” [4]
Merck state that “Millions of doses of the SEQUIVITY vaccine platform have safely been used by veterinarians in swine herds for more than ten years since the USDA first issued the license in 2012.” This is becasue Merck purchased Harrisvaccines who first gained USDA approval in September 2012.
TGA Advertising Code defines a “serious form of a disease”
Legislation changes to Australia’s Therapeutic Goods Advertising Code defines a “serious form of a disease” was restricted in 2015, and opened up in June 29, 2018 update, to be anything deemed “medically accepted” as a serious disease or a diagnostic test available (see Section 28). [1, 2]
FDA: first-in-class drug approval paves the way for RNA-based medicine
On August 10, 2018 the FDA approved patisiran (Onpattro) by Alnylam pharmaceuticals. This is a “first-in-class” drug is a small interfering RNA (siRNA) drug that work inside the cell at the RNA level. The FDA anticipates that [RNA-based Medicine] is the beginning of a new and exciting generation of therapeutics” [1, 2, 5]
The phase 3 trial included 225 patients with a “rare and frequently fatal” hereditary disease called transthyretin-mediated amyloidosis (hATTR), 148 were given the treatment [3]
Onpattro drug formulation contains “lipid excipients (DLin-MC3-DMA, DSPC, cholesterol, and PEG2000-C-DMG)”, because of this registration, the lipid nanoparticle ingredient DSPC (1,2-Distearoyl-sn-glycero-3-phosphocholine), which is also used in Pfizer’s mRNA COVID-19 vaccine as a structural lipid, is thus not conidered as “novel”, unlike the functional lipids ALC-0315 and ALC-0159. [4]
China’s Digital Dictatorship set up for 2020
It’s been in the pipeline for years: a sprawling, technological mass surveillance network the likes of which the world has never seen. Journeyman Pictures provide an insight into China’s Social Credit System (as scoring system) otherwise referred to as a digital dictatorship where every aspect of their life is monitored and rewarded or banned accordingly. [6]
The social credit scheme will become a “truly national unified system” i.e.mandatory by 2020. Computer algorithms with phones and 24/7 camera surveillance is scoring, rating and controlling “bad” citizens, thanks to mass scale implementation and acceptance of technology coupled with Artificial Intelligence. [2, 3, 4, 5, 9]
The scheme was first unveiled in 2014 and after 2020 the next five-year plan, which covers 2021 to 2025, the regime has set out its ambitions surveil people even more. [7]
China believes their scheme is a broad way to encourage trustworthiness in it’s citizens through their mix of measures.
Have you noticed more cameras installed in your local main street? Have you heard of Smart Cities? [8, 10, 11]
Johns Hopkins Report: 15 transformative technologies to reduce GCBRs
On October 9, 2018 the Johns Hopkins Center for Health Secuirty released a report highlighting 15 emerging technologies or categories of technologies, with further scientific attention and investment, as well as attention to accompanying legal, regulatory, ethical, policy, and operational issues have the potential to reduce global catastrophic biological risks (GCBR), as they present “potentially transformative” technologies which would “complement traditional approaches to prevention, preparedness, and response”. GCBRs is a concept defined in July 2017. The technologies include Self-Spreading Vaccines and Self-Amplifying mRNA Vaccines, and Micro-needle vaccine Patch. [1, 2, 3, 4]
This report highlights 15 technologies or categories of technologies that, with further scientific attention and investment, as well as attention to accompanying legal, regulatory, ethical, policy, and operational issues, could help make the world better prepared and equipped to prevent future infectious disease outbreaks from becoming catastrophic events.
“This report looks at technologies that are already available but have not been applied to an emergency situation before or are so new that they are still in development”, and “admits there are “substantial technical challenges” in genetically engineering a vaccine but technology such as the Crispr gene editing tool should make the job easier.”
2020 was too early for the self-spreading vaccines, but they are planned to be used for existing infectious diseases!! The WHO knowingly allowed this to occur for polio – they call it vaccine-derived polio!
BioNTech CEO predicts mRNA tech for rapid vaccine development
BioNTech‘s founder and CEO Dr Ugur Sahin was a “Spotlight” speaker at the October 16, 2018 World Health Summit and Grand Challenges annual meeting, which was held in Berlin, Germany. Other speakers included Bill Gates and Tedros Adhanom Ghebreyesus.
In Dr Sahin’s speech he said [1, 2]
“his company might be able to use its so-called messenger RNA technology to rapidly develop a vaccine in the event of a global pandemic”
BioNTech was founded in 2008 by Dr. Sahin with his wife, Dr. Özlem Türeci. By late 2018 it was still a little known European biotechnology start-ups which mostly focused on cancer treatments. [3] Like Moderna, BioNTech had never brought a product to market.
A month earlier, 0n August 16, 2018 BioNTech announced a partnership agreement with Pfizer to collaborate on an mRNA influenza vaccines.
In September 4, 2019 the “Bill & Melinda Gates Foundation invested $55 million to fund its work treating H.I.V. and tuberculosis”.
Starting September 24, 2019 BioNTech announces commencement of their Initial Product Offering (IPO). [3, 4]
Prior to all this, in 2001, Dr. Sahin and Dr. Türeci founded Ganymed Pharmaceuticals, which developed drugs to treat cancer using monoclonal antibodies, in October 2016 they sold that company for $1.4 billion.
Moderna became a public listed company
In December 2018, Moderna became a public listed company via the largest biotech initial public offering (IPO) in history, only to slump through 2019. Moderna which was founded in 2013, was saved by their COVID-19 vaccine in 2020 as they had never produced a single product before. [1, 2]
On May 10, 2019 Moderna announced the first human studies of mRNA vaccines said to demonstrate “a new technological approach to flu vaccine development and production”. [3]
Timeline pages:
1800s | 1900-1945 | 1946-1979 | 1980-1999 | 2000-2015 | 2016-2018 | 2019 | 2020 | 2021 | 2022 | 2023